Neuromodulation to Overcome Severe Restless Legs Syndrome
NCT: NCT07780032 · NOT_YET_RECRUITING
Brief Summary
This prospective, single-center, first-in-indication feasibility study will evaluate the safety and preliminary effectiveness of spinal cord stimulation (SCS) for the treatment of severe, treatment-refractory primary Restless Legs Syndrome (RLS). Participants will undergo implantation of the Saluda Medical Evoke® Spinal Cord Stimulation System and will be followed for 24 months with clinical, neurophysiological, and patient-reported outcome assessments.
Frequently Asked Questions
What is Neuromodulation to Overcome Severe Restless Legs Syndrome?
Neuromodulation to Overcome Severe Restless Legs Syndrome is a clinical trial registered under NCT07780032. Current status: NOT_YET_RECRUITING.
What is the status of NCT07780032?
The current status of NCT07780032 (Neuromodulation to Overcome Severe Restless Legs Syndrome) is: NOT_YET_RECRUITING.
When did Neuromodulation to Overcome Severe Restless Legs Syndrome start?
Neuromodulation to Overcome Severe Restless Legs Syndrome started on 2026-10.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.